Primary Biliary Cholangitis Therapeutics Market By Drug type (Primary Drug, Secondary Drug), By Distribution Channel (Hospital Pharmacies, Drugs Stores and Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

Primary Biliary Cholangitis Therapeutics Market By Drug type (Primary Drug, Secondary Drug), By Distribution Channel (Hospital Pharmacies, Drugs Stores and Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

The primary biliary cholangitis therapeutics market was valued at $683.95 million in 2022 and is estimated to reach $1.36 billion by 2032, exhibiting a CAGR of 7.1% from 2023 to 2032. Primary Biliary Cholangitis (PBC) therapeutics refers to the various treatment options available for managing and treating the condition. Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is a chronic autoimmune liver disease that primarily affects the small bile ducts within the liver. It is characterized by inflammation, destruction, and scarring of these bile ducts, leading to impaired bile flow and subsequent liver damage. The exact cause of PBC is still unknown, but it is believed to result from a combination of genetic predisposition and environmental triggers. The immune system mistakenly targets the bile ducts, leading to their destruction and the accumulation of bile within the liver. Over time, this ongoing inflammation and bile duct damage may progress to cirrhosis (scarring of the liver tissue) and liver failure. The goal of PBC therapeutics is to improve liver function, slow down disease progression, alleviate symptoms, and prevent complications.

Major factors that drive the growth of the global primary biliary cholangitis therapeutics market include rapid advancements in treatment of primary biliary cholangitis; rise in number of research regarding primary biliary cholangitis therapeutics; and increase in number of patients suffering from primary biliary cholangitis. For instance, according to the review article “autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis,” published in June 2021, the prevalence of primary biliary cholangitis and primary sclerosing cholangitis disease ranges from 1.9 to 40.2 per 100,000 people and has also grown over time. The increased prevalence is probably attributable to a combination of better disease recognition and data collection, and increased survival after the introduction of ursodeoxycholic acid (UDCA). 

Furthermore, surge in demand for primary biliary cholangitis therapeutics, increase in number of awareness programs regarding primary biliary cholangitis, and rise in number of clinical trials for the development of primary biliary cholangitis therapeutics boost the growth of primary biliary cholangitis therapeutics market. For instance, in October 2021, COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to treat immune disorders announced the U.S. FDA accepted an investigational new drug application (IND) for a proof-of-concept study of investigatory therapy CNP-104 of COUR Pharmaceuticals to address autoimmune causes of Primary Biliary Cholangitis (PBC). COUR nanoparticle platform (CNP) is a novel, proprietary system combining disease specific pathogenic antigens with state-of-the-art pharmaceutical nanoparticles that mimic normal removal of dead or dying cells from the body. PBC affects an estimated 130,000 people in the U.S., primarily women. Currently, healthcare professionals and patients rely on symptomatic therapies with limited results to slow down the progression of PBC but do not address its inherent cause, autoimmunity to PDC-E2 and the inflammatory cellular infiltration in the liver. This proof-of-concept trial will assess the safety and tolerability of CNP-104 in adults with PBC and aims to find the optimal dose level that strikes the best balance between safety and treatment activity.

In addition, increase in target population, rise in diagnosis rate of primary biliary cholangitis diseases, and surge in the prevalence of autoimmune diseases propel the market growth. However, lack of early diagnosis of primary biliary cholangitis, and limited treatment options are expected to restrict the growth of primary biliary cholangitis therapeutics market. On the contrary, surge in healthcare expenditure and unmet medical demands to get better treatment options in developing countries are expected to create lucrative opportunities for the expansion of the global market in the future. 

The primary biliary cholangitis therapeutics market is segmented on the basis of drug type, distribution channel, and region. On the basis of drug type, the market is bifurcated into primary drug and secondary drug. The primary drug segment is further categorized into obeticholic acid, ursodeoxycholic acid, others (PPARα/PPARδ agonist, and ileal bile acid transport inhibitors). On the basis of distribution channel, it is segregated into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

The major players profiled in the report are ABC Farmaceutici S.p.a., Alkem Laboratories Limited, AMAGEN INDIA LIFE SCIENCES, GENFIT, Intercept Pharmaceuticals, Inc., Ipsen Pharma, Leeford Healthcare Ltd, Lupin, Sun Pharmaceutical Industries Ltd., and Zydus Lifesciences Limited. These major players have adopted product approval, agreement, acquisition, and product launch as key developmental strategies to improve the product portfolio of the primary biliary cholangitis therapeutics market.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the primary biliary cholangitis therapeutics market analysis from 2022 to 2032 to identify the prevailing primary biliary cholangitis therapeutics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the primary biliary cholangitis therapeutics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global primary biliary cholangitis therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug type

Primary Drug
Type
Obeticholic Acid
Ursodeoxycholic Acid
Others
Secondary Drug

By Distribution Channel

Hospital Pharmacies
Drugs Stores and Retail Pharmacies
Online Pharmacies

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
ABC Farmaceutici S.p.a.
Alkem Laboratories Ltd.
AMAGEN INDIA LIFE SCIENCES
GENFIT
Intercept Pharmaceuticals, Inc.
Ipsen Pharma
Leeford Healthcare Limited
Lupin
Sun Pharmaceutical Industries Ltd
Zydus Lifesciences Limited

Please Note: It will take 7-10 business days to complete the report upon order confirmation.